ARCHIVES

Merck Serono Cancels Tecemotide Program In NSCLC, Including Two Phase III Trials

This article is from The Cancer Letter archive.

Vol. 37 No. 9 | September 26, 2014

Download PDF Visit The Full Archive

Related Articles

Maryland’s Greenebaum Cancer Center Wins NCI Designation.

September 12, 2008

NCI Cooperative Groups Recognized By ASCO For 50+ Years Of Clinical Trials.

June 1, 2007

In Brief: Margaret Holms Names Centers Branch Chief; Kimes To Recruit As Special Assistant

March 30, 1990

Rumors Preceded Broder’s Move

December 22, 1994

NCCN Updates Myeloma Clinical Practice Guidelines

September 26, 2003

In Brief: Lombardi Comprehensive Designation Renewed; Yale Plans Breast Cancer Lab

September 26, 1997